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Case Reports

De Novo CD3 Negative Hepatosplenic T-cell Lymphoma
Diagnostic Challenges and Pitfalls
Lucy Harn Kapur, MD; Yasser Khaled, MD; Melhem Solh, MD; David Ward, DO; Chung-Che Chang, MD

 Hepatosplenic T-cell lymphoma is a rare and aggressive
peripheral T-cell malignancy that is distinctively characterized by sinusoidal infiltration of mature medium-sized T
lymphocytes in the spleen and liver. The neoplastic cells
are classically surface CD3þ, CD2þ, CD5, CD4, and
CD8þ/ and manifest variable expression of markers
associated with natural killer (NK) cells such as CD16
and CD56. In this article, we report the first case to date of
a newly diagnosed de novo surface CD3 hepatosplenic Tcell lymphoma with circulating blastlike neoplastic cells
expressing NK-cell–associated markers. The lack of surface
CD3 expression, together with the expression of NK-cell–
associated markers and the leukemic presentation, leads to
significant diagnostic challenges in differentiating this
CD3 hepatosplenic T-cell lymphoma from NK-cell neoplasms, in particular aggressive NK-cell leukemia. The
related literature is reviewed, and the approaches for
adequate diagnosis of this novel situation are described.
(Arch Pathol Lab Med. 2014;138:969–973; doi: 10.5858/
arpa.2013-0074-CR)

S

ince the report of the first case in 1990 by Falco et al,
approximately 150 cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported, accounting for less
than 5% of all peripheral T/NK (natural killer)–cell
lymphomas.1,2 Hepatosplenic T-cell lymphoma occurs
predominantly in young men at a median age of 35 years.3
Twenty percent of the cases arise in patients with a history
of immunosuppression such as (but not limited to) organ
transplantation, Crohn disease, hepatitis B infection, and
intake of immunosuppressive drugs such as azathioprine
and additional medications used to treat rheumatoid
arthritis and systemic lupus erythematous.1–4 Unlike other
immune-mediated lymphomas, Epstein-Barr virus (EBV)
infection is not associated with the disease.3 Most of the
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cases are positive for cd T-cell receptor (TCR) gene
rearrangement and expression, although a few ab TCR
expressions have been reported recently.1 Patients with
hepatosplenic T-cell lymphoma have a poor survival rate,
despite chemotherapy and bone marrow transplantation
therapy.1,3,5 The median survival varies between 0 and 5
years, with rare complete remission.1
The neoplastic cells are classically surface CD3þ, readily
differentiating HSTCL from NK-cell neoplasms. Herein, we
describe a unique case of de novo surface CD3 HSTCL and
the challenge of differentiating it from NK-cell neoplasms,
particularly when only morphologic and immunophenotype
findings are available for the diagnosis.
REPORT OF A CASE
An 18-year-old man with a history of asthma was seen at the
emergency department with recurrent epistaxis, nausea, headache
for 3 days, and unintentional 9.1-kg weight loss during 3 weeks.
Clinical examination and computed tomography revealed an
enlarged spleen measuring 25.1 cm craniocaudally. There was no
lymphadenopathy. Laboratory test results showed severe thrombocytopenia (platelet count, 33/lL), mild anemia (hemoglobin
level, 11.8 g/dL), and normal total white blood cell count (8.8 3 103/
lL). Aspartate aminotransferase and lactate dehydrogenase levels
were elevated at 67 U/L and 535 U/L, respectively. Review of the
peripheral blood smear noted blastlike cells with finely dispersed
chromatin, prominent nucleoli, and fine cytoplasmic azurophilic
granules (Figure 1, A through C). The flow cytometric study of the
peripheral blood showed that the circulating neoplastic cells
(comprising about 40% of total white blood cells) seemed to be
of NK-cell lineage with expression of CD45 (bright), CD2, CD56,
CD11b, CD16 (partial), and cytoplasmic CD3, but the sample was
negative for surface CD3, CD57, CD4, CD5, CD7, CD8, TCR,
CD123, terminal deoxynucleotidyl transferase, CD34, B-cell markers, or myeloid markers (Figure 2, A through F). A bone marrow
aspirate and biopsy specimen revealed a hypocellular and
moderately fibrotic marrow with sinusoidal infiltration of neoplastic
cells best highlighted by cytoplasmic CD3 and CD56 on
immunohistochemistry (Figure 1, D and E). Paired box protein
PAX5, CD1a, terminal deoxynucleotidyl transferase, CD117,
granzyme B, and CD34 were all negative in the neoplastic cells,
ruling out B-cell involvement or acute lymphoid or myeloid
leukemia.
The surface CD3 neoplastic cell expression of NK-cell markers,
together with the leukemic presentation, led to an initial
impression of an NK-cell neoplasm, in particular aggressive NKcell leukemia (ANKL). However, the negative result of a
heterophile antibody test for mononucleosis and undetectable
serum EBV viral load rendered this diagnosis unlikely. Furthermore, molecular studies showed a clonal cd TCR gene rearrangeDe Novo CD3 Hepatosplenic T-cell Lymphoma—Kapur et al 969

Figure 1. A through C, Images of Giemsa and Wright–stained peripheral blood smears show blastlike cells with irregular nuclei, prominent nucleoli,
and finely dispersed chromatin (original magnifications 3100). Immunostaining of the bone marrow core biopsy specimen shows neoplastic cells
interspersed in the sinusoids with expression of cytoplasmic CD3 (D) and membranous CD56 (E) (original magnifications 340).

ment and cytogenetic abnormality of isochrome (7)(q10), indicating
the diagnosis of surface CD3 HSTCL.
Our patient received methotrexate and prednisone, followed by
the cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) regimen. Shortly after chemotherapy treatment, the
neoplastic population became surface CD3þ and TCR–cdþ (Figure
3, A through D). Subsequently, he has received a combination of
the chemotherapeutic drugs etoposide, methylprednisolone, highdose cytarabine, and cisplatin (ESHAP therapy), followed by
double umbilical cord blood transplantation. At 10 months after
transplantation, the patient remained in complete remission with
100% donor engraftment.

COMMENT
This unique surface CD3 HSTCL case highlights the
significant but often underappreciated overlap in clinical,
morphologic, and immunophenotype findings between
HSTCL and NK-cell neoplasms, in particular ANKL. For
example, clinically ANKL also occurs in young and middleaged adults, at a median age of 42 years.6,7 Patients with
ANKL can also initially be seen with hepatosplenomegaly
and constitutional symptoms such as fever, liver dysfunction, and fatigue. Lymphadenopathy occurs only occasionally, but cytopenia is common.7 In contrast to HSTCL,
ANKL has a strong association with EBV, and some patients
with ANKL may be seen with coagulopathies, hemopha970 Arch Pathol Lab Med—Vol 138, July 2014

gocytic syndrome, and multiorgan failure because of the
aggressive nature of the disease.7
Morphologically, HSTCL is characterized by homogeneous, mature, medium-sized postthymic T-lymphocytes
infiltrating into the sinusoids and sinuses of the liver and
spleen, respectively.1,3 The white pulp of the spleen can be
significantly reduced. Unlike in ANKL and our case, HSTCL
cells are typified by medium-sized nuclei, loosely condensed
chromatin, small inconspicuous nucleoli, and a rim of pale
cytoplasm.1,3 Overt leukemic presentation and lymphocytosis are rare at the initial examination; however, atypical
lymphocytes can be identified in the peripheral blood smear
of a few patients.3 Bone marrow infiltration of the neoplastic
lymphocytes with an intrasinusoidal pattern is present in
approximately two-thirds of cases.1 Erythrophagocytosis can
be seen in areas invaded by the neoplastic infiltrate.3
In comparison, ANKL is characterized by the presence of
circulating neoplastic NK cells, with a range of appearances
from cells that are slightly larger than large granular
lymphocytes to cells with irregular nuclear contour,
enlarged nuclei, immature chromatin pattern, and prominent nucleoli.7 Fine or coarse azurophilic granules are often
seen in the slightly pale or basophilic cytoplasm. However,
these characteristics were present in the circulating neoplastic cells of our patient with HSTCL. The morphologic
impression of the neoplastic cells seen in the peripheral
De Novo CD3 Hepatosplenic T-cell Lymphoma—Kapur et al

Figure 2. Flow cytometry of the patient before treatment shows that most of the neoplastic cells are in cyan. A small population of surface CD3þ and
CD5þ normal T cells is present in the background. The neoplastic cells have negative surface CD3 expression (B) and positive cytoplasmic CD3
expression (D). In addition, these cells express CD45 (bright), CD56, and CD16 (partial) but not CD57, CD5, CD7, CD22, or CD34 (A, C, E, and F).

blood of our case initially favored ANKL over HSTCL.
Varying degrees of bone marrow interstitial involvement by
the neoplastic cell infiltrate with reactive histiocyte hemophagocytosis are commonly seen in ANKL.8 Necrosis,
apoptosis, and vascular involvement, including angioinvasion and angiodestruction, have been reported in ANKL
tissue sections.7 Similar to HSTCL, tumor cells of ANKL can
also infiltrate the liver and spleen in the sinusoids and the
red pulp (wall vessels), respectively.7
Immunophenotypically, the tumor cells of HSTCL usually
express surface CD3, CD2, and CD7 and lack CD4, CD5,
and CD8, with 15% of cases being CD4/CD8þ. The NKcell–associated markers CD11b, CD16, and CD56 are
variably expressed but are estimated to be present in 60%
to 70% of all cases. CD57 is usually negative.3 Cytotoxic
granule-associated protein and granzyme M are usually
expressed in the cells, while granzyme B and perforin are
often negative.3 Terminal deoxynucleotidyl transferase is
negative and is useful in differentiating HSTCL from Tlymphoblastic lymphoma, which is characteristically CD4/
CD8.
With the exception of lacking surface CD3 expression,
ANKL cases can show an immunophenotype that is almost
identical to that of HSTCL. The ANKL cases usually are
CD2þ, cytoplasmic CD3eþ, CD56þ, TIA-1þ, CD4, CD5, and
CD8.7 Similar to HSTCL, CD11b and CD16 show variable
Arch Pathol Lab Med—Vol 138, July 2014

expression, while CD57 is usually negative.8,9 Positive
granzyme B and perforin expression and germline configuration of the TCR in ANKL are features that are helpful in
distinguishing these 2 entities.7
Our case demonstrated significant morphologic and
immunologic overlap between HSTCL and NK-cell neoplasms. The circulating neoplastic cells of this case were
blastlike with large irregular nuclear contour and contained
scant azurophilic granules, findings commonly seen in
ANKL. Also similar to NK cells, the cells lacked surface
CD3 expression and expressed the NK-cell–associated
markers CD56, CD16, and CD11B. However, a diagnosis
of CD3 HSTCL was rendered by the lack of EBV infection,
positive TCR gene rearrangement, classic sinusoidal infiltrates of bone marrow, and characteristic cytogenetic finding
of isochrome 7q and trisomy 8. The absence of EBV infection
also excluded the possibility of systemic EBVþ T/NK-cell
lymphoproliferative disease of childhood, an entity that is
more prevalent in Asia and may also be seen with
hepatosplenomegaly and sinusoidal marrow infiltrates.10
The negative expression of CD34, CD117, and terminal
deoxynucleotidyl transferase ruled out the diagnosis of
myeloid or lymphoid leukemia, which may lead to the
circulating blastlike cells observed. The acute clinical course
argued against the diagnosis of chronic lymphoproliferative
disorder of NK cells. The lack of extranodal site involvement
De Novo CD3 Hepatosplenic T-cell Lymphoma—Kapur et al 971

Figure 3. Flow cytometry of the patient after treatment shows that the residual neoplastic cells highlighted in red have become surface CD3þ. The
neoplastic cells also express CD56 (C), negative T-cell receptor delta/gamma (TCR-dg) (B), and CD11b and CD16 (D) but not CD5 (A). The cells in
blue are normal T cells present in the background (CD3þ, CD5þ, and CD56 ).

and EBV infection did not support the possibility of the nasal
type of extranodal T/NK-cell lymphoma. Although biopsy of
the liver and spleen was not performed in this case, with the
exception of lacking surface CD3 expression, the clinical,
morphologic, immunophenotype, cytogenetic, and molecular findings are all classic for HSTCL and ruled out other
types of T-cell lymphoma.
Surface CD3 HSTCL at initial presentation has not been
previously reported to the best of our knowledge. There
have been case reports of both blastic transformation of the
neoplastic cells and the loss of surface CD3 marker in a few
cases of HSTCL at the time of relapse.11 CD3 is first
expressed in the cytoplasm of the prothymocytes. As the T
972 Arch Pathol Lab Med—Vol 138, July 2014

cells mature, CD3 is expressed on the surface membrane
and forms a complex with TCR, which is important for
activation of the T cells (ie, transducing stimulatory signals
after antigen-specific recognition). The blastlike morphology of circulating cells in our case and the larger cells and loss
of surface CD3 expression observed at presentation of
relapse reported by others suggest that the absence of
surface CD3 likely represents a blastic phase in the
development of HSTCL.5 The exact clinical significance of
this type of presentation has yet to be determined because of
the limited case reports at this time.
In conclusion, surface CD3 HSTCL with blastlike
morphology is a novel variant of HSTCL. The pathologist
De Novo CD3 Hepatosplenic T-cell Lymphoma—Kapur et al

should be aware of this entity when considering a diagnosis
of T/NK-cell neoplasm. This case highlights the overlap
between HSTCL and NK-cell neoplasms and the diagnostic
challenges in identifying surface CD3 HSTCL. It is crucial
to integrate clinical, morphologic, immunophenotype,
molecular, and cytogenetic findings to reach an adequate
diagnosis.
We thank Gary Pearl, MD, PhD, for reviewing and editing the
article and Li Ge, MD, for formatting the figures.
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4. Steurer M, Stauder R, Grünewald K, et al. Hepatosplenic -T-cell lymphoma
with leukemic course after renal transplantation. Hum Pathol. 2002;33(2):253–
258.

Arch Pathol Lab Med—Vol 138, July 2014

5. Weidmann E. Hepatosplenic T cell lymphoma: a review on 45 cases since
the first report describing the disease as a distinct lymphoma entity in 1990.
Leukemia. 2000;14(6):991–997.
6. Song SY, Kim WS, Ko YH, et al. Aggressive natural killer cell leukemia:
clinical features and treatment outcome. Haematologica. 2002;87(12):1343–
1345.
7. Gao LM, Liu WP, Yang QP, et al. Aggressive natural killer-cell leukemia
with jaundice and spontaneous splenic rupture: a case report and review of the
literature. Diagn Pathol. 2013;8:43. http://www.ncbi.nlm.nih.gov/pubmed/?
term¼Aggressiveþnaturalþkiller-cellþleukemiaþwithþjaundiceþandþ
spontaneousþsplenicþrupture%3Aþaþcaseþreportþandþreviewþofþ
theþliterature. Accessed July 1, 2013.
8. Ryder J, Wang X, Bao L, et al. Aggressive natural killer cell leukemia: report
of a Chinese series and review of the literature. Int J Hematol. 2007;85(1):18–25.
9. Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell
leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells.
Leukemia. 2004;18(4):763–770.
10. Kimura H, Ito Y, Kawabe S, et al. Epstein-Barr virus (EBV)–associated T/NK
lymphoproliferative disease in nonimmunocompromised hosts: prospective
analysis of 108 cases. Blood. 2012;119(3):673–686.
11. Khan WA, Yu L, Eisenbrey AB, et al. Hepatosplenic gamma/delta T-cell
lymphoma in immunocompromised patients: report of two cases and review of
literature. Am J Clin Pathol. 2001;116(1):41–50.

De Novo CD3 Hepatosplenic T-cell Lymphoma—Kapur et al 973

